$ Value
$18K
Shares
4,668
Price
$4
Filed
Feb 26
Insider
Name
Jorgensen Nathan D.
Title
Chief Financial Officer
CIK
0001842523
Roles
Transaction Details
Transaction Date
2026-02-24
Code
S
Table
Non-Derivative
Ownership
Direct
Equity Swap
No
Shares After
151,416
Footnotes
Represents shares of common stock of Voyager Therapeutics, Inc. (the "Corporation") sold, pursuant to a durable automatic sale instruction adopted by the reporting person on May 9, 2025, effecting the sell-to-cover election of the reporting person to satisfy tax withholding obligations, in connection with the vesting of restricted stock units on February 21, 2026. The sales do not represent a discretionary trade by the reporting person. | The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $3.61 to $3.86, inclusive. The reporting person undertakes to provide to the Corporation, any security holder of the Corporation, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in footnote (2) to this Form 4.
Filing Info
Jorgensen Nathan D.'s History
| Date | Ticker | Type | Value |
|---|---|---|---|
| 2026-02-24 | VYGR | ▼ | $18K |
| 2026-02-06 | VYGR | A | $0 |
| 2026-02-06 | VYGR | A | $0 |
| 2025-10-03 | VYGR | ▼ | $37K |
Other Insiders at VYGR (90d)
| Insider | Bought | Sold | Last |
|---|---|---|---|
|
Sandrock Alfred
President and CEO
|
— | $184K | 2026-04-02 |
|
Jorgensen Nathan D.
Chief Financial Officer
|
— | — | 2026-02-06 |
|
Swartz Robin
COO & CBO
|
— | $55K | 2026-02-24 |
|
Carter Todd Alfred
Chief Scientific Officer
|
— | $41K | 2026-02-24 |
|
Ferguson Toby
Chief Medical Officer
|
— | — | 2026-02-06 |
|
Shiferman Gregory L.
SVP and General Counsel
|
— | — | 2026-04-01 |